Fisher Asset Management LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fisher Asset Management LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 5,057 shares of the biopharmaceutical company’s stock after selling 608 shares during the quarter. Fisher Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $5,317,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quent Capital LLC increased its holdings in shares of Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 19 shares during the last quarter. Cetera Investment Advisers increased its holdings in shares of Regeneron Pharmaceuticals by 156.8% in the 1st quarter. Cetera Investment Advisers now owns 9,753 shares of the biopharmaceutical company’s stock valued at $9,387,000 after acquiring an additional 5,955 shares during the last quarter. Cetera Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 114.1% in the 1st quarter. Cetera Advisors LLC now owns 5,218 shares of the biopharmaceutical company’s stock valued at $5,022,000 after acquiring an additional 2,781 shares during the last quarter. Railway Pension Investments Ltd increased its holdings in shares of Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Railway Pension Investments Ltd now owns 28,100 shares of the biopharmaceutical company’s stock valued at $27,046,000 after acquiring an additional 400 shares during the last quarter. Finally, Hamilton Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 72.0% in the 1st quarter. Hamilton Wealth LLC now owns 461 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 193 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 0.2 %

Shares of Regeneron Pharmaceuticals stock opened at $754.87 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $82.95 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. The business has a fifty day simple moving average of $913.54 and a 200-day simple moving average of $1,020.69. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Finally, Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.